The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Talquetamab in patients with R/R myeloma & renal impairment: a retrospective cohort study
In this video, Shahzad Raza, MD, Cleveland Clinic, Cleveland, OH, briefly discusses a retrospective cohort study evaluating the use of talquetamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) and renal impairment. Dr Raza highlights that the analysis found similar outcomes in patients with end-stage renal disease or on hemodialysis compared to those without renal function issues, suggesting that talquetamab can be safely used in this population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
